Back to top
more

Amplify Weight Loss Drug & Treatment ETF: (THNR)

(Delayed Data from NYSE) As of Jun 12, 2025 03:30 PM ET

$23.92 USD

23.9218
4

+0.25 (1.08%)

Volume: 4

Zacks ETF Rank

This is our ETF rating system that serves as a timeliness indicator for ETFs over the next 6 months:

Zacks Rank Definition
1 Strong Buy
2 Buy
3 Hold
4 Sell
5 Strong Sell

See all the Top Ranked ETFs here - The complete list of all the top ranked ETFs

NA

ETF Quote Details

Previous Close 23.92
Open 23.77
Bid 23.65
Ask 23.79
Day Low-High 23.77-23.95
52wk Low-High 18.56-28.19
Volume 4
NAV (month end) 22.23
Premium (+)/Discount (-) (month end)+1.69

Zacks Premium Research for THNR

Zacks ETF Rank

This is our ETF rating system that serves as a timeliness indicator for ETFs over the next 6 months:

Zacks Rank Definition
1 Strong Buy
2 Buy
3 Hold
4 Sell
5 Strong Sell

See all the Top Ranked ETFs here - The complete list of all the top ranked ETFs

 NA
ETF Risk

Zacks proprietary quantitative models divide each set of ETFs following a similar investment strategy (style box/industry/asset class) into three risk categories- High, Medium, and Low. The aim of our models is to select the best ETFs within each risk category, so that investors can pick an ETF that matches their particular risk preference in order to better achieve their investment goals.

NA
ETF Report

ETF Expense Ratio

Expense Ratio 0.59%
Dividend (Yield) $0.22 (0.92%)
Issuer AMPLIFY ETFS

Benchmark for THNR

VETTAFI WEIGHT LOSS DRUG & TREATMENT IND

The VettaFi Weight Loss Drug & Treatment Index comprises of global companies who are manufacturers in the GLP-1 agonist pharmaceutical business or who enable such business.

Fund Summary for THNR

AMPLIFY WEIGHT LOSS DRUG & TREATMENT ETF

The Amplify Weight Loss Drug & Treatment ETF seeks investment results that generally correspond to the performance, before fees and expenses, of the VettaFi Weight Loss Drug & Treatment Index.